Ubs Group Ag Compugen LTD Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Compugen LTD stock. As of the latest transaction made, Ubs Group Ag holds 324,581 shares of CGEN stock, worth $681,620. This represents 0.0% of its overall portfolio holdings.

Number of Shares

324,581

Previous 236,571 37.2%

Holding current value

$681,620

Previous $428,000 15.89%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.41 - $1.93 $124,094 - $169,859	88,010 Added 37.2%	324,581 $496,000
Q3 2024 Nov 14, 2024	SELL	$1.56 - $2.1 $91,041 - $122,556	-58,360 Reduced 19.79%	236,571 $428,000
Q2 2024 Aug 13, 2024	SELL	$1.68 - $2.52 $35,899 - $53,849	-21,369 Reduced 6.76%	294,931 $495,000
Q1 2024 May 13, 2024	BUY	$1.75 - $2.95 $2,805 - $4,728	1,603 Added 0.51%	316,300 $816,000
Q4 2023 Feb 09, 2024	BUY	$0.53 - $2.0 $18,784 - $70,886	35,443 Added 12.69%	314,697 $623,000
Q3 2023 Nov 09, 2023	BUY	$0.88 - $1.31 $24,058 - $35,814	27,339 Added 10.85%	279,254 $259,000
Q2 2023 Aug 11, 2023	SELL	$0.57 - $1.38 $42,723 - $103,435	-74,953 Reduced 22.93%	251,915 $287,000
Q1 2023 May 12, 2023	BUY	$0.68 - $1.11 $61,157 - $99,830	89,937 Added 37.96%	326,868 $228,000
Q4 2022 Feb 08, 2023	SELL	$0.58 - $1.2 $39,323 - $81,358	-67,799 Reduced 22.25%	236,931 $170,000
Q3 2022 Nov 10, 2022	SELL	$0.66 - $2.32 $16,713 - $58,751	-25,324 Reduced 7.67%	304,730 $200,000
Q2 2022 Aug 10, 2022	SELL	$1.57 - $3.33 $124,003 - $263,013	-78,983 Reduced 19.31%	330,054 $611,000
Q1 2022 May 16, 2022	BUY	$2.76 - $4.64 $643,060 - $1.08 Million	232,993 Added 132.35%	409,037 $1.32 Million
Q4 2021 Feb 14, 2022	BUY	$4.09 - $7.16 $36,687 - $64,225	8,970 Added 5.37%	176,044 $756,000
Q3 2021 Nov 15, 2021	BUY	$5.8 - $8.02 $637,269 - $881,189	109,874 Added 192.09%	167,074 $997,000
Q2 2021 Aug 13, 2021	SELL	$6.87 - $9.16 $133,882 - $178,510	-19,488 Reduced 25.41%	57,200 $474,000
Q1 2021 May 12, 2021	BUY	$7.67 - $13.77 $105,822 - $189,984	13,797 Added 21.94%	76,688 $659,000
Q4 2020 Feb 11, 2021	SELL	$12.07 - $17.95 $121,351 - $180,469	-10,054 Reduced 13.78%	62,891 $762,000
Q3 2020 Nov 12, 2020	BUY	$14.16 - $19.45 $800,450 - $1.1 Million	56,529 Added 344.35%	72,945 $1.19 Million
Q2 2020 Jul 31, 2020	BUY	$6.97 - $17.12 $63,420 - $155,774	9,099 Added 124.35%	16,416 $247,000
Q1 2020 May 01, 2020	SELL	$5.79 - $11.83 $236,892 - $484,012	-40,914 Reduced 84.83%	7,317 $54,000
Q4 2019 Feb 14, 2020	SELL	$3.9 - $6.16 $55,422 - $87,539	-14,211 Reduced 22.76%	48,231 $288,000
Q3 2019 Nov 14, 2019	SELL	$3.01 - $4.49 $20,410 - $30,446	-6,781 Reduced 9.8%	62,442 $264,000
Q2 2019 Aug 14, 2019	SELL	$2.8 - $4.14 $62,610 - $92,574	-22,361 Reduced 24.42%	69,223 $266,000
Q1 2019 May 14, 2019	BUY	$2.35 - $4.19 $13,724 - $24,469	5,840 Added 6.81%	91,584 $379,000
Q4 2018 Feb 14, 2019	SELL	$2.17 - $3.8 $231,089 - $404,673	-106,493 Reduced 55.4%	85,744 $186,000
Q3 2018 Nov 14, 2018	SELL	$3.0 - $4.05 $227,544 - $307,184	-75,848 Reduced 28.29%	192,237 $740,000
Q2 2018 Aug 14, 2018	SELL	$3.15 - $4.7 $151,140 - $225,510	-47,981 Reduced 15.18%	268,085 $885,000
Q1 2018 May 15, 2018	BUY	$2.5 - $4.45 $748,865 - $1.33 Million	299,546 Added 1813.23%	316,066 $1.41 Million
Q4 2017 Feb 14, 2018	SELL	$2.35 - $4.0 $86,569 - $147,352	-36,838 Reduced 69.04%	16,520 $42,000
Q3 2017 Nov 14, 2017	SELL	$2.75 - $3.95 $85,002 - $122,094	-30,910 Reduced 36.68%	53,358 $203,000
Q2 2017 Aug 14, 2017	BUY	N/A	62,884 Added 294.07%	84,268 $320,000
Q1 2017 Nov 14, 2017	BUY	N/A	21,384	21,384 $92,000

Others Institutions Holding CGEN

# of Institutions

Shares Held

13.4M

Call Options Held

44.9K

Put Options Held

8.1K

View Full List

About COMPUGEN LTD

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $182M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

More about CGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account